Abivax
Abivax is a clinical-stage biotechnology company developing obefazimod, a first-in-class oral miR-124 enhancer, for ulcerative colitis and Crohn's disease, with NDA submission planned for Q4 2026.
- Company typePublic
- Founded2013
- HeadquartersParis, France
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Abivax does
Abivax SA is a clinical-stage biotechnology company headquartered in Paris, France, with dual listings on Euronext Paris and Nasdaq (ticker ABVX). Founded in 2013, the company is developing obefazimod (ABX464), an investigational oral once-daily small molecule that is the first and only clinical-stage enhancer of microRNA-124 (miR-124), a natural regulator of the inflammatory response. Under dysregulated inflammatory conditions, enhanced miR-124 expression stabilizes multiple cytokines and chemokines toward homeostatic levels, addressing multiple pathways simultaneously to potentially reduce compensatory immune escape. Obefazimod is in Phase 3 development for moderately to severely active ulcerative colitis (positive ABTECT induction and maintenance data, with NDA submission targeted for Q4 2026) and Phase 2b for Crohn's disease (ENHANCE-CD, data anticipated mid-2027). Preclinical evidence also indicates dual anti-inflammatory and anti-fibrotic activity.
Abivax has no commercial revenue and operates at a loss, with FY2025 R&D expenses of €177.8 million and net loss of €336.1 million. The cash position of €530.4 million at year-end 2025 has been augmented by a $920 million public offering in July 2026, extending runway into Q2 2029. The company is investing heavily in US commercialization infrastructure, including a Waltham, Massachusetts headquarters and a senior leadership team recruited from Takeda (Entyvio), AstraZeneca-target CinCor, Landos Biopharma, and Roche/Genentech, with a first US launch targeted for 2027. Beyond obefazimod, Abivax holds a proprietary chemical library supporting follow-on compound research in inflammation.
Abivax firmographics
Firmographics- Name
- Abivax
- Legal name
- Abivax SA
- Website
- http://www.abivax.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Abivax is a clinical-stage biotechnology company developing obefazimod, a first-in-class oral miR-124 enhancer, for ulcerative colitis and Crohn's disease, with NDA submission planned for Q4 2026.
- Ownership category
- akta.pro rank
Where Abivax is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices4 records
Markets served
Abivax business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- No Current Revenue: Abivax is a clinical-stage biotechnology company with no approved products or commercial revenue. The company reported a net loss of €48.5 million in Q1 2026 and a full-year 2025 net loss of €336.1 million. R&D expenses were €49.5 million in Q1 2026 and €177.8 million for full-year 2025.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Abivax product offering
Product offeringCore offering
Abivax is developing obefazimod (ABX464), an investigational oral once-daily small molecule and the first clinical-stage enhancer of microRNA-124 (miR-124) expression in immune cells, designed to stabilize the dysregulated inflammatory response in chronic inflammatory diseases. The lead indication is moderately-to-severely active ulcerative colitis (Phase 3 ABTECT program) with Phase 2b development in Crohn's disease (ENHANCE-CD), supported by a proprietary chemical library of follow-on candidates.
Product overview
Abivax is a clinical-stage biotechnology company developing obefazimod, an oral small molecule therapeutic that enhances microRNA-124 (miR-124) expression to stabilize the immune response. The company's lead product candidate, obefazimod (ABX464), is in Phase 3 development for ulcerative colitis and Phase 2b for Crohn's disease. Abivax is also evaluating obefazimod in combination therapy for UC and exploring other inflammatory indications through follow-on compound research based on the same mechanistic concept.
Differentiator
Problem solved
Functional benefit
Products and services
- Obefazimod (ABX464) Obefazimod is an investigational, orally administered once-daily small molecule therapeutic and the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. It is being developed for chronic inflammatory diseases, with lead indication in moderately to severely active ulcerative colitis (Phase 3 ABTECT) and Phase 2b development in Crohn's disease (ENHANCE-CD).
Quantifiable outcome
- Clinical remission rate of 50.8% (25mg) and 51.3% (50mg) versus 10.4% placebo at Week 44 in Phase 3 ABTECT maintenance trial
- +5 more outcomes
Companies that use Abivax
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Abivax technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Abivax partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor.
- European Crohn's and Colitis Organization (ECCO)minorMedical congress where Abivax presented 22 abstracts at ECCO 2026 Annual Congress including first evidence of anti-fibrotic activity and new clinical efficacy and safety analyses for obefazimod.
- Dechert LLPminorDechert advised Abivax on a €49.2 million financing that funded Phase 3 trials of obefazimod for ulcerative colitis.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
Abivax competitors and assessment
Company assessmentDirect peers
- Pfizer: Pfizer markets Velsipity (etrasimod), an oral S1P modulator approved for ulcerative colitis, making it a directly comparable oral UC competitor launched into the same gastroenterology prescriber base.
- Bristol Myers Squibb: BMS commercializes Zeposia (ozanimod), another oral UC therapy, positioning it as a directly comparable oral competitor with overlapping physician call points and payer access dynamics.
Broad incumbents
- Eli Lilly: Lilly markets Omvoh (mirikizumab) for ulcerative colitis and Crohn's disease, making it a directly comparable IBD biologic competitor with established gastroenterology commercial infrastructure.
- AbbVie: AbbVie dominates the IBD market with Skyrizi and Rinvoq, alongside its legacy Humira franchise; it is the leading incumbent that Abivax's oral obefazimod would need to compete against for share of voice and payer access.
- Johnson & Johnson: J&J markets Stelara and Tremfya in IBD, two of the largest-selling UC and Crohn's therapies; it is a broad incumbent whose immunology franchise shapes the standard of care Abivax must displace.
- Takeda: Takeda markets Entyvio (vedolizumab), a ~$4.7B IBD biologic, and is the company Abivax hired its incoming CCO from — a directly comparable UC franchise and benchmark for Abivax's commercial ramp.
Emerging players
- Landos Biopharma: Landos is a smaller IBD-focused biotech (now part of AbbVie) whose leadership overlaps with Abivax's CMO, making it a thematic emerging peer in ulcerative colitis pipeline development.
Others
- Alnylam Pharmaceuticals: Alnylam is a leader in RNA-based therapeutics and shares a mechanistic adjacency with Abivax, whose entire MOA is built around enhancing the microRNA miR-124 — making it thematically relevant as an RNA-platform comparator.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Abivax social profiles
Digital presenceAbivax financial estimates
Financial estimateRevenue estimate
Valuation estimate
Abivax leadership team
Management profileNumber of profiles
Profiles17 records
Abivax funding detail
Funding detailFunding overview
Funding rounds10 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Abivax M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Abivax
What does Abivax do?
Abivax is developing obefazimod (ABX464), an investigational oral once-daily small molecule and the first clinical-stage enhancer of microRNA-124 (miR-124) expression in immune cells, designed to stabilize the dysregulated inflammatory response in chronic inflammatory diseases. The lead indication is moderately-to-severely active ulcerative colitis (Phase 3 ABTECT program) with Phase 2b development in Crohn's disease (ENHANCE-CD), supported by a proprietary chemical library of follow-on candidates.
Is Abivax a public or private company?
Abivax is a public company. It is classified as public and is currently operating.
When was Abivax founded?
Abivax was founded in 2013. It employs 101 to 250 people.
Where is Abivax based?
Abivax is headquartered in Paris, France, in the Europe region.
How does Abivax make money?
One revenue line is on record: no Current Revenue.
Who are Abivax's main competitors?
Direct peers on record are Pfizer and Bristol Myers Squibb. Broad incumbents are Eli Lilly, AbbVie, Johnson & Johnson and Takeda. Landos Biopharma is listed as an emerging player. Alnylam Pharmaceuticals is listed as an others.
Does Abivax have an API?
No public API is recorded for Abivax.